CA-NETAPP
28.8.2024 22:16:33 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the original intelligent data infrastructure company, today announced new capabilities that support VMware Cloud Foundation deployments. Mutual customers will be able to leverage NetApp solutions to right-size their IT environments to run VMware workloads at scale efficiently.
For more than a decade, NetApp and VMware, recently acquired by Broadcom Inc., have collaborated to ensure the success of their joint customers and help them unlock the full value of their VMware investments. During that time, NetApp has been a key engineering design partner with VMware and is continuing to drive innovation in highly available, scalable and performant storage as a design partner for its Next-Generation vSphere Virtual Volumes (vVols). Now, NetApp is announcing new capabilities that will enable joint customers to run their VMware deployments more efficiently.
“NetApp and Broadcom are working together to take the uncertainty out of hybrid cloud environments,” said Jonsi Stefansson, Senior Vice President and Chief Technology Officer at NetApp. “More than 20,000 customers rely on NetApp to support their VMware workloads. NetApp's continued close collaboration with Broadcom following the acquisition of VMware ensures our solutions seamlessly interoperate so our mutual customers can leverage a single intelligent data infrastructure to operate their VMware workloads more efficiently.”
NetApp is helping optimize costs, simplify operations, and increase flexibility for customers running VMware environments by offering:
- Expanded Support for VMware Cloud Foundation (VCF): NetApp and Broadcom customers will now be able to simplify their VCF hybrid cloud environments by using NetApp ONTAP® software for all storage requirements, including standard and consolidated architectures. The latest release of ONTAP Tools for VMware (OTV) will support SnapMirror® active sync to provide symmetric active-active data replication capabilities for NetApp storage systems running VMware workloads. SnapMirror active sync allows customers to operate more efficiently by offloading data protection from their virtualized compute and improving data availability.
- New Capabilities for Azure VMware Solution (AVS): To support customers that are extending or migrating their vSphere workloads to the cloud, customers can now leverage Spot Eco by NetApp with AVS reserved instances to get the most value out of their deployments. Using Spot Eco to manage AVS reserved instances while also using Azure NetApp Files to offload data storage can reduce compute costs significantly.
- Enhanced VM Optimization Features for NetApp Cloud Insights: NetApp is introducing Cloud Insights VM Optimization, expanding its comprehensive solution for optimizing virtual environments, including VMware. Cloud Insights VM Optimization will give customers tools to reduce costs by increasing VM density, run storage at the best price-to-performance ratio for their environment, and monitor their entire environment to ensure availability, performance, and adherence to configuration best practices across the entire stack. To help customers optimize the compute, memory and storage resources of their VMware environments, NetApp is also offering customers a free 30-day trial of Cloud Insights to most cost-effectively migrate to the new VMware software subscriptions.
These offerings follow last month’s release of enhancements to NetApp BlueXP™ disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across hybrid cloud environments with newly added support for VMFS datastores.
“As organizations modernize infrastructure with VMware Cloud Foundation, they want to know that the services upon which they rely from industry-leaders such as NetApp will continue to work seamlessly and deliver the value they have come to expect,” said Paul Turner, Vice President of Products, VCF Division at Broadcom. “Having NetApp as a close collaborator helps our mutual customers deploy innovative data and storage services on top of their private cloud platform, and ensure they are getting the most value out of their VMware environments.”
“We have made Microsoft Azure the cloud of choice for VMware environments and offer fast and cost-effective solutions enabling many customers to move their VMware workloads to the cloud,” said Brett Tanzer, Vice President of Product Management at Microsoft. “As VMware customers navigate changes to operating virtualized environments, we have given our customers a way to lock in secure and predictable pricing over multiple years. NetApp's data management and cloud observability capabilities help our customers ensure those deployments are delivering the return on investment they need.”
“In an ever more complicated world of cloud, data, and infrastructure operations, IT teams are increasingly looking for holistic platforms over point solutions,” said Scott Sinclair, Practice Director, Enterprise Strategy Group. “These joint updates from NetApp and Broadcom enable customers to use NetApp’s intelligent data infrastructure to consolidate multiple data operations onto a single platform with industry-leading data management and CloudOps capabilities. That will help customers drive greater operational and infrastructure efficiencies that reduce the total cost of ownership for their VMware investments.”
Additional Resources
About NetApp
NetApp is the original intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828604243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom